SUBSCRIBE
SUBSCRIBE

TG Therapeutics, Inc.

NEWS
Pharm Country
TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 American Society of Clinical Oncology Annual Meeting
June 4, 2021
 · 
11 min read
Pharm Country
TG Therapeutics to Present at Upcoming Investor Conferences - May 27, 2021
May 27, 2021
 · 
1 min read
Policy
TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab in Combination with UKONIQ® (umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
May 25, 2021
 · 
13 min read
Pharm Country
TG Therapeutics Announces Data Presentations at Upcoming Medical Meetings
May 13, 2021
 · 
5 min read
Business
TG Therapeutics Provides Business Update and Reports First Quarter 2021 Financial ResultsConference call to be held today, Monday, May 10, 2021 at 8:30 AM ET
May 10, 2021
 · 
11 min read
Business
TG Therapeutics to Host Conference Call on First Quarter 2021 Financial Results and Business UpdateConference call to be held Monday, May 10, 2021 at 8:30 AM ET
May 6, 2021
 · 
1 min read
Pharm Country
TG Therapeutics to Participate in the B. Riley Securities Neuroscience ConferenceFireside chat scheduled for Wednesday, April 28, 2021 at 9:00 AM ET
April 26, 2021
 · 
1 min read
Pharm Country
Samsung Biologics and TG Therapeutics Expand Collaboration for the Large Scale Manufacture of Ublituximab
April 25, 2021
 · 
7 min read
Drug Development
TG Therapeutics Announces Launch of the ULTRA-V Phase 3 Trial Evaluating the Triple Combination of UKONIQ™ (umbralisib), Ublituximab, and VenetoclaxULTRA-V Phase 2 trial has reached completion of patient enrollment
April 21, 2021
 · 
13 min read
Pharm Country
TG Therapeutics Announces Positive Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at American Academy of Neurology 73rd Annual Meeting
April 16, 2021
 · 
12 min read
Pharm Country
TG Therapeutics to Host Investor & Analyst Event to Preview Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple SclerosisWebcast to be held tomorrow, April 16, 2021 at 8:30 AM ET
April 15, 2021
 · 
6 min read
Pharm Country
TG Therapeutics Completes Rolling Submission of Biologics License Application to the U.S. Food and Drug Administration for Ublituximab in Combination with UKONIQ™(umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia
March 29, 2021
 · 
13 min read
BioCapital
Clinical Catch-Up: March 8-12
March 12, 2021
 · 
10 min read
 · 
Mark Terry
Drug Development
TG Therapeutics Announces Publication of Results from the UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed or Refractory Indolent non-Hodgkin Lymphoma in the Journal of Clinical Oncology
March 9, 2021
 · 
12 min read
Pharm Country
TG Therapeutics to Present Results from the ULTIMATE I & II Phase 3 Trials Evaluating Ublituximab in Multiple Sclerosis at the Upcoming American Academy of Neurology 73rd Annual Meeting
March 4, 2021
 · 
6 min read
Pharm Country
TG Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
March 4, 2021
 · 
1 min read
Load More
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
JOBS